Chiesi could have its work cut out to persuade NICE, the health technology appraisal institute for England and Wales, that its enzyme replacement therapy Lamzede (velmanase alfa) is a cost-effective treatment for the ultra rare condition alpha-mannosidosis. The institute this week published draft guidance stating that it had too many doubts about the available evidence and the company’s economic modelling.
Draft guidance published May 23 is based on recommendations from the highly specialised evaluation committee
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?